Literature DB >> 15676208

Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB.

Chunhua Dai1, Ik-Joo Chung, Sanford B Krantz.   

Abstract

OBJECTIVE: The aim of this study was to explore the mechanism by which increased erythropoiesis occurs in polycythemia vera (PV).
METHODS: CD34(+) and erythroid colony-forming cells (ECFC) were purified from normal or PV peripheral blood and then incubated in the presence of erythropoietin (EPO) to generate erythroid progenitor cells. Measurement of proliferation by Ki-67 staining, TUNEL assays to measure apoptosis, and Western blots for detection of Akt/PKB and glycogen synthase kinase 3 (GSK3) phosphorylation were performed in both normal and PV erythroid progenitors.
RESULTS: Polycythemia vera erythroid progenitor cells generated 60% more cells compared to normal cells in liquid medium cell cultures. TUNEL assays revealed no difference between PV and normal erythroid progenitors, but Ki-67 staining for cell proliferation showed many more positive cells in the PV samples. A marked increase of phosphorylation of Akt/PKB occurred in the day-8 erythroid progenitors of 4/5 PV patients, compared to normal cells, after incubation with either stem cell factor (SCF) or EPO. PV cells also had much greater glycogen synthase kinase 3 (GSK3) alpha,beta phosphorylation compared to normal cells after incubation with SCF or EPO. These results are parallel to the cellular hypersensitivity of PV cells to SCF and EPO previously reported.
CONCLUSIONS: Increased erythropoiesis in PV is associated with increased cellular proliferation and increased phosphorylation of Akt/PKB and GSK3. This study provides additional insight into the pathogenesis of PV and the regulation of normal erythropoiesis, even though a specific molecular defect of the disease is still not apparent.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15676208     DOI: 10.1016/j.exphem.2004.10.017

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  15 in total

Review 1.  The molecular mechanisms that control thrombopoiesis.

Authors:  Kenneth Kaushansky
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

2.  Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway.

Authors:  Wei Zhao; Claire Kitidis; Mark D Fleming; Harvey F Lodish; Saghi Ghaffari
Journal:  Blood       Date:  2005-10-04       Impact factor: 22.113

3.  AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation.

Authors:  Saghi Ghaffari; Claire Kitidis; Wei Zhao; Dragan Marinkovic; Mark D Fleming; Biao Luo; Joseph Marszalek; Harvey F Lodish
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113

Review 4.  Hematopoietic growth factors, signaling and the chronic myeloproliferative disorders.

Authors:  Kenneth Kaushansky
Journal:  Cytokine Growth Factor Rev       Date:  2006-10-20       Impact factor: 7.638

5.  Identification of an acquired JAK2 mutation in polycythemia vera.

Authors:  Runxiang Zhao; Shu Xing; Zhe Li; Xueqi Fu; Qingshan Li; Sanford B Krantz; Zhizhuang Joe Zhao
Journal:  J Biol Chem       Date:  2005-04-29       Impact factor: 5.157

6.  ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(-/-) mice.

Authors:  Safak Yalcin; Dragan Marinkovic; Sathish Kumar Mungamuri; Xin Zhang; Wei Tong; Rani Sellers; Saghi Ghaffari
Journal:  EMBO J       Date:  2010-11-26       Impact factor: 11.598

7.  Thermal injury of the skin induces G-CSF-dependent attenuation of EPO-mediated STAT signaling and erythroid differentiation arrest in mice.

Authors:  John G Noel; Benjamin J Ramser; Jose A Cancelas; Francis X McCormack; Jason C Gardner
Journal:  Exp Hematol       Date:  2017-09-01       Impact factor: 3.084

Review 8.  Thrombopoietin in normal and neoplastic stem cell development.

Authors:  Kenneth Kaushansky; Helen M Ranney
Journal:  Best Pract Res Clin Haematol       Date:  2009-12       Impact factor: 3.020

9.  Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.

Authors:  Jacob P Laubach; Ping Fu; Xiaohong Jiang; Kelly H Salter; Anil Potti; Murat O Arcasoy
Journal:  Exp Hematol       Date:  2009-10-06       Impact factor: 3.084

10.  RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features.

Authors:  Giacomo Coltro; Giada Rotunno; Lara Mannelli; Carmela Mannarelli; Sara Fiaccabrino; Simone Romagnoli; Niccolò Bartalucci; Enrica Ravenda; Eleonora Gelli; Emanuela Sant'Antonio; Mrinal M Patnaik; Ayalew Tefferi; Alessandro M Vannucchi; Paola Guglielmelli
Journal:  Blood Adv       Date:  2020-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.